News: Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

68.55USD
27 Mar 2015
Change (% chg)

$0.53 (+0.78%)
Prev Close
$68.02
Open
$68.38
Day's High
$68.61
Day's Low
$68.00
Volume
613,174
Avg. Vol
823,050
52-wk High
$77.30
52-wk Low
$65.95

Search Stocks
Select another date:

Fri, Mar 20 2015

Fitch Maintains Baxter International on Rating Watch Negative

(The following statement was released by the rating agency) CHICAGO, March 20 (Fitch) Fitch Ratings has maintained Baxter International Inc.'s (Baxter; NYSE: BAX) long- and short-term ratings on Rating Watch Negative. Fitch placed the company's ratings on Negative Watch in March 2014 when Baxter announced it plans to spin off its BioScience business. A full list of the company's ratings follows at the end of this press release. The ratings apply to approximately $9.21 billion of debt outsta

BRIEF-Co don AG reaches milestone for EU-wide approval

* Reaches milestone for EU-wide approval: successful patient recruitment for phase III clinical trial Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Caverion provides building systems for Baxter in Austria

* Entered into a contract with pharmaceutical group Baxter in framework of a consortium with Molin

Baxter's blood disorder drug gets FDA approval

- (This Oct. 24 story has been corrected to remove paragraph saying that Obizur will compete with Biogen Idec Inc's BIIB.O Eloctate. Eloctate is approved to treat congenital hemophilia A, not acquired hemophilia A)

CORRECTED-UPDATE 1-Baxter's blood disorder drug gets FDA approval (Oct 24)

(Corrects to remove paragraph saying that Obizur will compete with Biogen Idec Inc's Eloctate. Eloctate is approved to treat congenital hemophilia A, not acquired hemophilia A)

UPDATE 1-Baxter's blood disorder drug gets FDA approval

Oct 24 - Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder.

Baxter's blood disorder drug gets FDA approval

Oct 24 - Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder.

UPDATE 1-AstraZeneca cancer drug pipeline gets boost from European green light

* EMA also backs new drugs from Pfizer, Baxter, Clinuvel (Adds AstraZeneca comment, further details)

Medical products push Baxter profit above estimate

- Medical device and drug maker Baxter International Inc reported a higher-than-expected quarterly profit, as sales in its medical products business continued to grow.

UPDATE 1-Medical products push Baxter profit above estimate

Oct 16 - Medical device and drug maker Baxter International Inc reported a higher-than-expected quarterly profit, as sales in its medical products business continued to grow.

Select another date:
Search Stocks